抗体夹心酶联免疫吸附法测定重组E.coli L-天冬酰胺酶及药代动力学研究

目的 建立大鼠血浆中重组E .coliL 天冬酰胺酶的抗体夹心酶联免疫吸附测定法 ,并进行药代动力学研究。方法 应用重组E .coliL 天冬酰胺酶免疫家兔 ,分离IgG ,用DEAE 纤维素柱色谱纯化 ,辣根过氧化物酶标记抗体 ,建立抗体夹心酶联免疫吸附法 ,测定大鼠血浆中重组E .coliL 天冬酰胺酶浓度。结果 方法的线性范围为 1～6 4U·L- 1 ,血药浓度与时间的关系符合二房室模型 ,初期和末端的T1 2 分别为 0 5 0～ 0 5 7h和 2 4 5～ 3 0 2h ,AUC与剂量成正比。结论 建立的抗体夹心酶联免疫吸附法在灵敏度、特异性、线性范围、精密度和回收率等方面 ,满足药代动力学研究要求。实验方法和重组E .coliL

E·coli L-天冬酰胺酶B细胞抗原表位氨基酸残基Lys^(196)对其抗原性的影响

目的:研究重组E.coli L-天冬酰胺酶B细胞抗原表位中关键氨基酸残基对其抗原性的影响。方法:以Ala为替代残基,对抗原表位192TPARKHTS199中Lys196进行PCR定点突变,双向免疫扩散法和间接ELISA法分析新型重组E.coli L-天冬酰胺酶的抗原性。结果:采用双向免疫扩散法和间接ELISA法检测,与重组E.coli L-天冬酰胺酶相比,新型重组E.coliL-天冬酰胺酶与重组E.coli L-天冬酰胺酶抗体结合率下降64%。结论:通过对重组E.coli L-天冬酰胺酶B细胞抗原表位关键残基的定点突变有效地降低了其抗原性。

Pharmacokinetics of Recombinant E. coli L-asparaginase in Rats

The distribution of ^(125)I recombinant E. coli L-asparaginase in tissues ororgans and the excretion in urine, feces and bile were studied with in vivo radioactive tracertechnique. The amount of radioactivity excreted in urine, feces and bile within 24 h afterintravenous administration of ^(125)I recombinant E. col L-asparaginase to rats was 68.95% ,4.44%and 5.36% of the dose respectively. ^(125)I recombinant E. coli L-asparaginase in plasma samples wasdetermined. The levels of structural intact molecule in plasma samples were evaluated by SDS-PAGEand bio-imaging analyzer system. Pharmacokinetic parameters were assessed with a model-dependentmethod. The concentration-time curves of recombinant E. coli L-asparaginase after intravenousinjection at 1 250 IU·kg^(-1), 2 500, IU·kg^(-1), 5 000 IU·kg^(-1) to rats were consistent withthe two-compartment model. The first and terminal elimination t_(1/2) were 0.52 ~ 0.63 h and 2.39 ~2.76 h respectively. AUC was linearly related to the doses. The results of distribution in tissuesor organs and excretion in urine suggested that the metabolites of the enzyme were cleared bymechanisms of urinary excretion. Pharmacokinetics parameters of recombinant E. coli L- asparaginasein rats are warranted for the design of future clinical trials.